Suggested remit - To appraise the clinical and cost effectiveness of pembrolizumab with axitinib within its marketing authorisation for untreated metastatic renal cell carcinoma
 
Status In progress
Process STA 2018
ID number 1426

Provisional Schedule

Committee meeting: 1 22 January 2020
Expected publication 27 May 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Consultees

Companies sponsors Merck Sharp & Dohme (Pembrolizumab)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Kidney Cancer Support Network
  Kidney Cancer UK
  National Kidney Federation
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Bristol-Myers Squibb (ipilimumab, nivolumab) (confidentiality agreement signed)
  Ipsen Ltd (cabozantinib) (confidentiality agreement signed)
  Pfizer (sunitinib) (confidentiality agreement signed)
  EUSA Pharma (tivozanib) (confidentiality agreement signed)
  Novartis (pazopanib) (confidentiality agreement not signed)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
17 May 2019 Invitation to participate
03 December 2018 Following an update from the company, NICE has rescheduled the appraisal and it is expected to begin in mid-May 2019.
27 June 2018 - 25 July 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
21 March 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance